secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0000950170-24-012748
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences raises $6.2M in public offering, regains Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Gross proceeds ~$6.2M from sale of 128,470 shares and 1,236,530 pre-funded warrants, plus 2,730,000 Class D warrants at $4.53 combined price.
- Class D warrants exercisable at $4.53/share, expire in 5 years; pre-funded warrants at $0.0001/share, no expiration.
- Net proceeds to fund Phase 1a/1b studies for GEM-SSI (surgical site infection) and GEM-AKI (cardiac surgery AKI), plus preclinical GEM-CKD work.
- Nasdaq confirmed on Feb 8, 2024 that REVB regained compliance with minimum $1.00 bid price rule after 11 consecutive trading days above $1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/revb-20240205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-012748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer